Pharmasset Falls on Rival Abbott Hepatitis C Therapy Results

Pharmasset Inc., developer of anti-viral medicines, plunged today after Abbott Laboratories said interim study results of its rival experimental hepatitis C therapy showed high cure rates.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.